In such a case, given the preclinical results presented in the current study, the use of exogenous IL-6 or IL-10 and NO donors as therapeutic strategies may not be appropriate because of their specificity to only protect one type of graft and even NO donors can be prejudicial if steatosis is indeed present. This evidence concerns the gene IL10 and steatosis.